Casi Pharmaceuticals (CASI) said Thursday its board received an updated non-binding proposal from Chairman and CEO Wei-Wu He to acquire its entire business operations in China for $20 million.
The proposal includes the acquisition of all of the company's license-in, distribution, and related rights in Asia, excluding Japan, related to certain of its pipeline products. The latest offer updates a preliminary non-binding proposal that He submitted in June 2024, Casi said.
The company's shares were 11.5% higher in premarket trading.